Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. CON: Novel oral agents provide an attractive alternative to chemotherapy in metastatic hormone-sensitive prostate cancer
No abstract available
Source: Current Opinion in Urology - Category: Urology & Nephrology Tags: POINT-COUNTERPOINT Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Hormones | Oral Cancer | Prostate Cancer | Urology & Nephrology